Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002003
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Phase II Study of NovantroneR Mitoxantrone and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas
Sponsor:
Lederle Laboratories
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Phase II Study of NovantroneR Mitoxantrone and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas
Status:
COMPLETED
Status Verified Date:
1992-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride Novantrone and etoposide in the treatment of patients with HIV associated lymphomas
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 3-100 | None | None | None |